<DOC>
	<DOCNO>NCT00356109</DOCNO>
	<brief_summary>A study test non-inferiority preprandial HIIP [ also know AIR® Inhaled Insulin Powder ] [ AIR® register trademark Alkermes , Inc . ] compare preprandial injectable insulin ( insulin lispro ) respect HbA1c 6 month treatment patient type 1 diabetes mellitus . This study design also examine insulin antibody level AIR Insulin -treated patient compare injectable insulin-treated patient type 1 diabetes . The present study intend determine preprandial AIR Insulin non-inferior preprandial injectable insulin ( insulin lispro ) respect mean change HbA1c baseline endpoint 6 month patient type 1 diabetes .</brief_summary>
	<brief_title>Evaluate Efficacy Insulin Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes least 24 month Have HbA1c less equal 11 % Patients insulin regimen involve 2 3 preprandial injection per day least 2 month Nonsmoker Require daily total insulin dosage great 150 U screen Patients current past history asthma , chronic obstructive pulmonary disease , clinically relevant pulmonary disease Systemic glucocorticoid therapy Clinical sign symptoms liver disease , acute chronic hepatitis History lung transplantation and/or lung cancer Diagnosed pneumonia 3 month prior screen History renal transplantation Active untreated malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>